Herms F, Lambert J, Grob JJ, et al. - Through an observational retrospective study done in nine French oncodermatology units, of 166 individuals with locally advanced basal cell carcinoma (laBCC) with complete response (CR) on vismodegib who discontinued treatment between March 2012 and January 2016, researchers assessed long-term responses, predictive factors, and management of relapse following discontinuation of vismodegib. The only variable independently related to a greater risk of relapse was LaBCC to the limbs and trunk. Twenty-seven individuals, during follow-up, who had a relapse, were retreated with vismodegib, with an objective response in 23 and qualification for surgery in 24. Hence, following vismodegib discontinuation, a long-term response is common. However, most cases that encounter relapse still react to vismodegib rechallenge.